Consensus AB Science Deutsche Boerse AG

Equities

A8D

FR0010557264

Market Closed - Deutsche Boerse AG Other stock markets 02:03:10 2024-04-26 EDT			5-day change	1st Jan Change
1.806 ^EUR	-0.66%		-5.45%	-50.25%

04-04	AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	MT
04-03	AB Science: reconsideration possible for masitinib in ALS	CF

Evolution of the average Target Price on AB Science

Price target over the last 5 years

History of analyst recommendation changes

5e0f56a080c3f3d0dc511.dCJvOQrOLfNiucbzJLTsAom6fAys72u3ADbvQUtlE3M.HRo2a3OnH7ItjLGsXuvZWPvwKyGZjlvfQ2HZIConIiAcbBxWU715sRqPpQ~18a5746e1dcdc1664a3bf432e080de8f

Analyst Recommendations on AB Science

AB Science : Masitinib Treatment Against Pancreatic Cancer Boosts Survival Rates	20-12-04	MT
SCIENCE : AB Science: Chardan Capital Markets initiates coverage with a BUY recommendation on AB Science and a target price of €30	15-05-05	GL

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.936 EUR

Average target price

6.895 EUR

Spread / Average Target

+256.15%

High Price Target

10 EUR

Spread / Highest target

+416.53%

Low Price Target

3.79 EUR

Spread / Lowest Target

+95.76%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar